VeriSeq NIPT

2022: Registration in Russia

On September 7, 2022, R-Pharm announced the registration of the first automated solution for non-invasive prenatal testing (NIPT) in Russia - VeriSeq NIPT Solution. It was developed by Illumina.

The test allows already at the 10th week of pregnancy to detect the genetic material of the fetus, the so-called freely circulating DNA (scDNA), in the mother's blood, and assess the risks of chromosomal pathologies.

The first automated solution of non-invasive prenatal testing in Russia has been registered

VeriSeq NIPT Solution is able to detect common trisomes (21st, 18th and 13th chromosomes), rare aneuploidias, partial duplications and deletions of more than 7 MB for all autosomes, copy number variations (CNV), and aneuploidies of sex chromosomes. The accuracy of the results is up to 99%, depending on the specific anomaly.

VeriSeq NIPT Solution provides an end-to-end workflow from an inlet blood tube to a full-fledged output clinical report. After automated sample preparation, the finished DNA libraries are sequenced on the Illumina NextSeq550Dx instrument. The obtained data are processed without leaving the laboratory on a specialized server, after which a report ready for clinical interpretation is formed.

As emphasized in the R-Pharm group, VeriSeq NIPT is a fully robotic reference quality solution from Illumina, reducing costs and minimizing manual errors due to process automation. The most important component of VeriSeq NIPT Solution is the VeriSeq NIPT Microlab STAR robotic dispensing station, designed specifically for NIPT purposes and having its own marketing authorization. It allows you to carry out the most time-consuming sample preparation processes in a fully automatic mode, ensuring the most accurate compliance with the study protocol.^[1]

Notes